AlphAIalphai — Financial news for AI agents
aol.co.ukAUG 242 min read$LLY

New diabetes and weight loss pill available from pharmacies from today

Eli Lilly's new diabetes and weight loss pill, Orforglipron (Foundayo), is now available in UK pharmacies. Approved by the MHRA, it's licensed for patients with a BMI of 30+ or 27-30 with weight-related conditions. The NHS is assessing it for potential rollout. Pharmacies warn of counterfeit versions.

Original reporting
aol.co.uk
Published Aug 24, 2026, 12:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 1:06 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
New diabetes and weight loss pill available from pharmacies from today — source image
Source · aol.co.uk
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

Regulatory approval expands Lilly's product portfolio and could capture market share from injectable competitors.

02

Market read

First UK oral GLP‑1 approval may drive sales growth and influence obesity/diabetes treatment landscape.

03

What to watch

Potential pricing negotiations with NHS could limit upside.

Relevance 7/10Novelty 8/10Timing: available today in UK pharmacies

Background

Eli Lilly's Foundayo is an oral GLP‑1 drug for type‑2 diabetes and weight loss, previously only available as injectables.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly received MHRA approval for its oral GLP‑1 pill Foundayo, now available in UK pharmacies.

Expected impact

Potential upside as UK launch drives revenue and expands addressable market.

Evidence & confidence

Regulatory approval and immediate pharmacy availability represent a new revenue stream for a large pharma.

Market effects

Sector

May accelerate competition in oral GLP‑1 market and pressure peers.

Regional

UK launch could influence NHS formulary decisions and European rollout.

Global

First European approval could set precedent for other markets.

Counterpoint

What could challenge this read

Oral formulation may face adherence challenges compared to injectables.

Key entities

  • Company
    Eli Lilly

    Pharmaceutical manufacturer of Foundayo.

  • Regulator
    MHRA

    UK Medicines and Healthcare products Regulatory Agency.

Read at source← All news

Also covered by

3 outlets

Related articles

AUG 24
$LLYMedAI 8/10

New weight loss and diabetes pill available in UK pharmacies

Eli Lilly's weight loss and diabetes pill, Orforglipron (Foundayo), is now available in UK pharmacies, approved by the MHRA. It's the first GLP-1 pill for weight loss in Europe. The company is working with NHS on potential rollout. Dosage starts at 0.8mg, increasing monthly. Pharmacists warn about counterfeit versions.

lbc.co.uk2 min
AUG 24
$LLYMed

New once-daily weight loss pill now available in pharmacies across UK

Eli Lilly's new weight loss and diabetes pill, orforglipron (Foundayo), is now available in UK pharmacies. It's the second GLP-1 pill for weight loss in the UK, after Wegovy. The MHRA authorized it earlier this month. Eli Lilly is working with the NHS on potential health service rollout. The pill is for patients with BMI 30+ or BMI 27-30 with weight-related conditions. Dosage starts at 0.8mg, increasing monthly. Pharmacists highlight its significance for patients avoiding injectables.

the-independent.com2 min
AUG 21
$BMYMedAI 8/10

Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK

Bristol-Myers Squibb (BMY) will invest $2.3B in a Houston plant, part of a $40B U.S. investment. Eli Lilly (LLY) won UK approval for its weight-loss drug, Foundayo. BMY's investment aims to boost domestic manufacturing, while LLY expands internationally. Both companies face challenges, including patent expirations for BMY and market competition for LLY. Hedge funds show mixed interest in both stocks.

insidermonkey.com3 min
AUG 21
$BMYMedAI 8/10

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.

finance.yahoo.com3 min